Likewise, Shh-medulloblastomas are also amenable to SMO inhibitor treatment; in particular, sonidegib has shown superior antitumor efficacy (ORR: 55%) compared to vismodegib (ORR: 17%) in a systemic review and meta-analysis of phase I and phase II clinical trials of pediatric and adult medulloblastoma patients treated with sonidegib and vismodegib [197]. The gene discussed is SHH; the disease is medulloblastoma.